Vikas Dandekar

Journalist - Indian pharma & healthcare. Views own

[email protected]

[Vikas Dandekar @VikasReports]

2024 wrap up time! #Thread some good, some sobering and some that were tough. In January, Rajeev Raghuvanshi, India’s DCGI laid out the roadmap for the big changes in an exclusive Q&A. An ongoing task and much is expected:
https://t.co/3G1cnG4BZE

[Chirag Barjatya @chiragbarjatya]

Why no one is talking about this? In Himachal pradesh almost 2 lakh people are affected by antibiotic resistance. Around 600 factories are dumping pharma waste without any care. Most of them are dumping directly in rivers. Sirsa river TDS is cross 1000. Thank you Dainik bhaskar for covering this.

[Alen @Alen_ET]

While no formal pullback has been announced, industry voices have grown louder. Longer-term relief, most agree, lies in revised rates and a more predictable payment cycle.

https://t.co/E6c7oTiu3x

@VikasReports

[Anirban Chowdhury @AnirbanET]

Sun Pharma’s $11.75B Organon deal is India’s biggest pharma bet.

Women’s health, biosimilars and 50 established brands can catapult Sun to a global leader.

But scale comes with leverage and complexity. Integration, cash flows, and execution will matter more than strategy slides.

I speak to @arijitbarman76 and @VikasReports who scooped every bit of the story: discussion to fruition

[Vikas Dandekar @VikasReports]

@sruthijith Thank you Boss ! Glad we traversed this well. @arijitbarman76 salutes!

[SK @sruthijith]

Already seeing people claiming credit but Sun Pharma’s high voltage acquisition of Organon, the biggest M&A by an Indian company since Tata’s purchase of Corus, was an exclusive broken by Arijit and Vikas in the 19 Jan edition of ET. They got every follow up story right and correctly called the acquisition going through in last night’s edition. Months of dogged pursuit.

When it comes to Arijit’s track record in big ticket M&A, I’m reminded of what Tyson said about Ali during a heartwarming meeting of the legends: “Every head must bow, every tongue must confess, he’s the greatest of all time”.

Take a bow, comrades. @arijitbarman76 and pharma don @VikasReports

[arijit barman @arijitbarman76]

@SunPharma_Live set to acquire Organon for $12.5 bn, its biggest till date. @EconomicTimes exclusive @VikasReports @ETPharma
https://t.co/dnqmsg1udg

[Harsh Goenka @hvgoenka]

Winners of the Oscars of business #ETAwards
Business Leader: Sajjan Jindal ‘steels’ the spotlight…
Company of the Year: Airtel gets connected
Lifetime Achievement: Cyrus Poonawalla gives excellence a perfect shot
K P Singh builds it brick by brick
Business Reformer : Chandrababu Naidu scripts reform…
Global Indian: Neal Mohan hits play globally
Businesswoman: Vibha Padalkar secures the future

[arijit barman @arijitbarman76]

Will they, won't they? We have been on this story since January. Now as it reaches the last leg, we wait for the final . If there is one man it's #dilipsanghvi and one co @SunPharma_Live that can dare to do something bold as @Organon Our #newsbreak in the
@EconomicTimes @eqt #gruenthal
@VikasReports
https://t.co/gCe8wwi7T9

[Sandeep K. Rathod @GenericIPguy]

Exceptionally candid conversation and worth every minute.

@VikasReports gets a very result using years of industry knowledge and relationships he builds ✔️

https://t.co/bhOEBKM0Lb

[Dr. Reddy’s Laboratories Ltd @drreddys]

@VikasReports @EconomicTimes Watch the full episode here:
https://t.co/iuF3beNXun

Listen to the full episode here:
https://t.co/i6nHxMYbqU

[Anirban Chowdhury @AnirbanET]

At 30, @gvprasad was handed a crisis with no guidance.
“It’s your problem. Go deal with it.”

@VikasReports

[Anirban Chowdhury @AnirbanET]

Dilip Sanghvi: 'Running a business based on what investors think is a fool's errand.'

Glenn Saldanha: 25 years, countless failures, then a $1.9B AbbVie deal.

Listen in to our latest Corner Office Conversation. With @VikasReports

https://t.co/FTdjaWI0JW

[Anirban Chowdhury @AnirbanET]

The next global divide will be on compute.

At the India AI Impact Summit, one fault line stood out:

AI makers vs AI markets.

This isn’t one gap. It’s five stacked together.

Here’s the 5-layer breakdown:

[Dinesh S. Thakur @d_s_thakur]

2/n
in India was a US citizen and a resident of California?

Most class action tort cases from overseas are dismissed in the US for lack of standing. Here was a perfect case where a US citizen and California resident was a member of the putative class. @kaunain_s details her

[Dinesh S. Thakur @d_s_thakur]

@kaunain_s 5/n
read these excellent series of in-depth reports from Vidhi on how we regulate healthcare facilities, how decrepit our medical councils are and how dysfunctional our consumer courts are in this matter:

https://t.co/Xdx4ELfIWZ

[Vikas Dandekar @VikasReports]

Must read....

[Dinesh S. Thakur @d_s_thakur]

Good piece in today's ET from @VikasReports & @Teensthack on how our regulations and legal justice system extracts pain and misery from those who already fall victim to the pharma/device company's fraudulent activities.

Did you know that among those who received an implant 1/n

[Dinesh S. Thakur @d_s_thakur]

Good piece in today's ET from @VikasReports & @Teensthack on how our regulations and legal justice system extracts pain and misery from those who already fall victim to the pharma/device company's fraudulent activities.

Did you know that among those who received an implant 1/n

[Teena Thacker @Teensthack]

Johnson and Johnson faulty hip implant case represents one of the most significant crises in medical device history.

Was there an option to tap the US courts and reach a better solution?

Revisiting it with @VikasReports @JNJNews

[Teena Thacker @Teensthack]

Podcast alert ‼️
@VikasReports

[Economic Times @EconomicTimes]

Mankind Pharma targeting #1 position domestically. Piramal doubling down on ADCs & hospital generics. With Indian pharma's emphasis on innovation, the next 20 years should be a big leap for the industry.
Nandini Piramal, chairperson, @PiramalPharma and @junejaaarjun, COO of Mankind Pharma, speak to ET's pharma editor @VikasReports in the latest episode of Corner Office Conversation.
@IPAOfficialPage

Watch the full conversation here:
https://t.co/ebYd8Cuuyl